Pyxis Oncology (PYXS) has opened 2026 with Q1 results that keep the focus on scaling the top line while absorbing ongoing losses, with trailing 12 month revenue at about US$13.9 million and a basic EPS loss of roughly US$1.28 alongside net income losses of about US$79.6 million. Over recent quarters, the company has seen revenue move from US$0 in Q1 2025 to US$11.0 million in Q4 2025, while quarterly basic EPS losses have ranged between about US$0.29 and US$0.35 per share. For investors, that mix of growing revenue against persistent EPS pressure keeps margins in the spotlight as the key lens for judging this latest update.

See our full analysis for Pyxis Oncology.

With the headline numbers on the table, the next step is to compare them with the most widely held narratives around Pyxis Oncology to see which views the results support and which they call into question.

US$13.9m trailing revenue alongside widening annual loss

• Over the last twelve reported months, Pyxis Oncology generated about US$13.9 million of revenue while reporting a trailing net loss of around US$79.6 million and a basic EPS loss of roughly US$1.28.
• What stands out for a bullish view that focuses on revenue growth is that the trailing 12 month revenue base of about US$13.9 million sits against a five year pattern of losses that have widened by about 4.4% per year. Any focus on the forecast 76.3% annual revenue growth rate has to be weighed against the fact that the company is still loss making on a similar scale to the US$18.1 million loss reported in Q4 2025 alone.
  • Supporters of the bullish angle can point to the move from US$0 revenue in Q1 2025 to US$11.0 million by Q4 2025 and the forecast 76.3% annual revenue growth, but critics will note that net losses across the same period remained in a fairly tight band between roughly US$18.1 million and US$22.0 million per quarter.
  • That tension between a growing top line and continued quarterly EPS losses of around US$0.29 to US$0.35 per share means any growth focused thesis relies on the company eventually converting this revenue base into better margins rather than just scaling up the size of the loss.

Less than one year of cash runway heightens financing risk

• The company is reported to have less than one year of cash runway, which is flagged as a major financial position risk alongside ongoing losses, including a trailing 12 month net loss of about US$79.6 million.
• Bears highlight the short cash runway and continued unprofitability as central concerns, and the recent numbers give that view concrete support because the trailing net loss of about US$79.6 million and quarterly losses such as the US$22.0 million loss in Q3 2025 leave little room for self funding, so any renewal of cash resources is likely to depend on external capital or partnerships rather than internal cash generation.
  • Skeptics also point out that the company is currently unprofitable and is expected to remain unprofitable for at least the next three years, which sits uncomfortably next to the limited cash runway and the pattern of quarterly basic EPS losses between US$0.29 and US$0.35 per share over 2025.
  • For a reader watching risk, this means the combination of less than one year of cash runway and a trailing revenue base of only about US$13.9 million does not yet offset the scale of annual losses, so funding and dilution questions are likely to stay in focus.

P/S of 10.3x sits below industry and peer benchmarks

• On a price to sales basis, the stock trades at about 10.3x, compared with roughly 10.9x for the broader US biotech industry and about 34.4x for peers, while the current share price is US$2.28.
• What is interesting for investors weighing bullish versus cautious views is that this lower P/S multiple comes at the same time as strong trailing revenue growth and ongoing losses. While valuation looks comparatively lower than peers on revenue, bears can still point to the trailing net loss of about US$79.6 million and a basic EPS loss of about US$1.28 over the last twelve months as reasons why the discount might persist until the business model shows clearer progress toward profitability.
  • Supporters of a more optimistic stance may argue that paying 10.3x sales for a company with forecast revenue growth of about 76.3% per year compares favorably with peers at 34.4x, but that argument is constrained by the fact that the company is still loss making and not expected to reach profitability within three years.
  • Critics counter that a relatively low P/S ratio does not automatically signal a bargain when cash runway is under one year and quarterly net losses, such as the US$18.1 million loss in Q4 2025, continue to absorb capital without yet pointing to self sustaining operations.

To see how other investors are stitching these revenue, loss, and cash runway threads into a single story, it is worth looking at how the wider community frames Pyxis Oncology today 📊 Read the what the Community is saying about Pyxis Oncology.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Pyxis Oncology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

The mix of growth hopes, cash concerns, and ongoing losses leaves plenty of room for debate. Check the data yourself and move quickly to firm up your own view, starting with a clear look at the 2 key rewards and 3 important warning signs.

See What Else Is Out There

Pyxis Oncology combines US$13.9 million in trailing revenue with continued net losses of about US$79.6 million and less than one year of cash runway, which keeps financing risk front and center for investors.

If that mix of ongoing losses and a short cash runway feels uncomfortable, it is worth comparing with companies screened for stronger buffers using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.